Dmytro Kharkov

Cullinan Therapeutics to unveil initial clinical data on CD19 and BCMA T cell engagers

Cullinan Therapeutics to unveil initial clinical data on CD19 and BCMA T cell engagers
Cullinan unveils T cell therapy data

Cullinan Therapeutics is set to host an Immunology Day for investors and analysts on June 10 to present initial clinical data from its CD19- and BCMA-targeted T cell engager therapies for autoimmune diseases.

The company aims to provide insights into the potential of its innovative T cell therapy pipeline, which targets immune system disorders by engaging specific cell types. This event may offer investors and industry observers a first look at promising early-stage efficacy data in a research area that has drawn increasing attention from biotechnology firms.

Cullinan previously reported first-quarter 2026 financial results, along with updates on developmental milestones for its pipeline assets. Earlier this year, the firm gained FDA acceptance of its NDA for zipalertinib in advanced EGFR exon 20 NSCLC. These developments reflect the company's continued progress in both oncology and autoimmune research.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.